A Practical Approach to Managing IBS: Understanding and Applying the Evidence for Optimal Care
William Chey, MD, and Amy Foxx-Orenstein, DO, offer their expert insights into the diagnosis and management of irritable bowel syndrome (IBS). These experts discuss several cases that illustrate issues you might encounter when caring for patients with IBS and will help you navigate the diagnosis and treatment of this common complaint, including making the IBS diagnosis without unnecessary diagno...
|
|
Advances in the Management and Treatment of Non-Hodgkin Lymphoma
This text-based CME activity provides guidance and expert recommendations on the initial diagnostic workup and therapy selection, as well as an overview of the latest data on recently approved and emerging therapeutic options for patients with B-cell non-Hodgkin lymphoma (NHL). Although recent treatment advances do not provide a cure, they do, however, provide longer remissions and improve patie...
|
|
|
Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics
Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of a...
|
Analysis of Recently Published Acute Lymphoblastic Leukemia Articles /
In this CME activity Elias Jabbour, MD, reviews some of the recent clinical developments in advanced acute lymphoblastic leukemia. We invite you to learn more about the current and emerging standards of care, as well as safety and efficacy data from the select clinical trials, in patients with acute lymphoblastic leukemia.
CONTENT AREAS
• CD19-positive ALL
• A bispecific T-cell engager...
|
|
|
Emerging Concepts in the Recognition and Management of SLE
Michelle Petri, MD, MPH, and Daniel J. Wallace, MD, FACP, MACR, provide their experience and insight into the diagnosis and management of systemic lupus erythematosus (SLE), with perspectives for both general practitioners and rheumatologists.
CONTENT AREAS
• Signs and symptoms
• Diagnosis
• Organ-threatening disease
• Non-organ-threatening disease
• Treatment goals
• Adhe...
|
|
Facing Opioid Use Disorder: Connecting Primary Care to Patients Through Best Available Evidence
Peter D. Friedmann, MD, MPH, FASAM, FACP and Jonna I. Gaberman, MD, provide their insights into the myriad challenges faced by clinicians in managing patients with opioid use disorder. The faculty discuss tools and factors to consider in the identification and assessment of persons with opioid use disorder. Treatment principles, including the importance of patient collaboration, comprehensive tr...
|
Idiopathic Pulmonary Fibrosis: Navigating a Complex Disease in an Evolving Treatment Landscape
Steven D. Nathan, MD, discusses how idiopathic pulmonary fibrosis (IPF) differentiates from other interstitial lung diseases. Dr. Nathan presents the impact of an early and accurate diagnosis of IPF, common symptoms, and the diagnostic tools and criteria used for an accurate diagnosis. In addition, Dr. Nathan reviews the significance of high-resolution computed tomography (HRCT) and what IPF loo...
|
|
Latest Development and Expert Outlook of Management of Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal, disabling disease,
commonly associated with skin psoriasis, and estimated to affect up to 42% of the
approximately 7.5 million people in the United States with psoriasis. There remains an
ongoing challenge among clinicians to diagnose and treat patients, as well as to stay abreast
of optimal treatment strategies. In this ...
|
|
NAVIGATING BIOSIMILARS: TRANSLATING EVIDENCE INTO CLINICAL PRACTICE
Leonard Calabrese, DO, and Steven Feldman, MD, PhD, provide their insights into the dynamic world of biosimilars, first highlighting key features of biologics and the rigorous scientific requirements for demonstrating biosimilarity.
|
|
New Treatments and a New Approach to Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are a diverse group of malignant tumors that occur throughout the soft tissues. Although rare, the possibility of a sarcoma must be considered in the differential diagnosis of any suspicious mass.
This CME activity provides guidance through the initial diagnostic workup and reviews the latest data of new and emerging therapeutic options for advanced, metastatic STS....
|
|
Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action
Evan Ya-Wen Yu, MD, provides his insights into the evolving management of patients with castration-resistant prostate cancer (CRPC) and the implications of the genomic landscape on CRPC. Since clinical trial evidence does not clearly inform sequencing strategies, Dr. Yu weaves his insight into this conundrum using 3 cases, with suggestions to help the urologist individualize treatment.
CONTE...
|
|
Psoriatic Arthritis - Posters and Abstracts from San Diego
Philip J. Mease, MD, clinical professor at the University of Washington School of Medicine in Seattle, Washington, and director of the Rheumatology Clinical Research Division at Swedish Medical Center, provides his perspectives on key posters, presented at the American College of Rheumatology annual meeting, on the treatment of patients with psoriatic arthritis.
CONTENT AREAS
• Psoriatic a...
|
|
Psoriatic Arthritis Posters and Abstracts from San Diego Source: American College of Rheumatology Annual Meeting held November 3-7, 2017 in San Diego, California
Philip J. Mease, MD, clinical professor at the University of Washington School of Medicine in Seattle, Washington, and director of the Rheumatology Clinical Research Division at Swedish Medical Center, provides his perspectives on key posters, presented at the American College of Rheumatology annual meeting, on the treatment of patients with psoriatic arthritis.
Proceed at your own pace and i...
|
|
The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes
John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM).
CONTENT AREAS
• Unmet needs
• Experience with basal insulin/GLP-1RA
• FRC basal insulin/GLP-1RAs
• Insulin degludec/liraglu...
|
|